S100A9 and obesity disorder: Small molecule inhibitor ABR-215757 (Paquinimod) was identified as a promising candidate, enhancing tube formation in the human umbilical vein endothelial cells (HUVECs) and reducing inflammatory markers.<h4>Conclusion</h4>Targeting S100A9 may restore endothelial function and offer novel therapeutic strategies for obesity-related hypertension in children.